Propanc Biopharma, Inc.: Form 10-Q for the period ended Mar 31, 2018
Filed with the SEC on May 10, 2018 and accepted by EDGAR at May 10, 2018, 17:23 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2018-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2018-01-01 to 2018-03-31 | $75.1k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2017-07-01 to 2018-03-31 | $1.7m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2018-01-01 to 2018-03-31 | −$807.1k | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2017-07-01 to 2018-03-31 | −$3.4m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2018-01-01 to 2018-03-31 | $830.9k | us-gaap:InterestExpense |
| Interest expense | 9 months2017-07-01 to 2018-03-31 | $2.2m | us-gaap:InterestExpense |
| Income tax | 3 months2018-01-01 to 2018-03-31 | −$485 | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2017-07-01 to 2018-03-31 | −$180.8k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2018-01-01 to 2018-03-31 | −$1.5m | us-gaap:NetIncomeLoss |
| Net income | 9 months2017-07-01 to 2018-03-31 | −$5.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2018-01-01 to 2018-03-31 | −$0.06 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 9 months2017-07-01 to 2018-03-31 | −$0.42 | us-gaap:EarningsPerShareBasicAndDiluted |
| Cash and equivalents | At period end2018-03-31 | $9.3k | us-gaap:Cash |
| Current assets | At period end2018-03-31 | $99.3k | us-gaap:AssetsCurrent |
| Total assets | At period end2018-03-31 | $110.7k | us-gaap:Assets |
| Current liabilities | At period end2018-03-31 | $6.9m | us-gaap:LiabilitiesCurrent |
| Long-term debt | At period end2018-03-31 | $4.5m | us-gaap:LongTermDebt |
| Shareholders' equity | At period end2018-03-31 | −$6.8m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001493152-18-006584. Last ingested by Listed: Oct 29, 2026, 17:01 ET. Listed shows no prices and gives no investment advice.